Estrella Immunopharma, Inc. Common Stock
N/A
USD
N/A
N/A
...
Chart
Financials
Description
ESLA Company Description
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.
ESLA Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view ESLA Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More
All
Government
Consumer Interest
SEC Filings
ESG/Other
Recent trades of ESLA by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by ESLA's directors and management
Government lobbying spending instances
U.S. Patents
New patents grants
Government Contracts
Federal grants, loans, and purchases
WallStreetBets
Number of mentions of ESLA in WallStreetBets Daily Discussion
ESLA News
Recent insights relating to ESLA
CNBC Recommendations
Recent picks made for ESLA stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in ESLA
Corporate Flights
Flights by private jets registered to ESLA
Our Analysis